載入...
Searching for novel multimodal treatments in oligometastatic pancreatic cancer
BACKGROUND: Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of...
Na minha lista:
| 發表在: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7106565/ https://ncbi.nlm.nih.gov/pubmed/32228504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06718-3 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|